Loading...
•
Sep 30, 2022
Eton Q3 2022 Earnings Report
Eton Pharmaceuticals reported financial results, showing significant growth in product sales and royalties.
Key Takeaways
Eton Pharmaceuticals reported a 315% increase in product sales and royalties compared to the prior year, driven by growth in ALKINDI SPRINKLE and Carglumic Acid. The company also acquired Betaine Anhydrous and received FDA approval for Zonisade™.
Reported seventh straight quarter of sequential growth in product sales and royalty revenue.
Total revenue reached $3.2 million, a 315% increase year-over-year.
ALKINDI SPRINKLE sales grew by 183% compared to the prior year.
Acquired Betaine Anhydrous, a third FDA-approved rare disease product.
Revenue by Segment
Forward Guidance
Eton expects Betaine Anhydrous to be accretive to earnings in 2023 and anticipates additional product launches in 2023 and 2024.
Positive Outlook
- Betaine Anhydrous shares the same prescriber base as Carglumic Acid.
- Betaine Anhydrous expected to be accretive to Eton’s earnings in 2023.
- Potential for additional product launches in 2023 and 2024.
- Zonisade was launched in October, triggering a $5 million milestone payment.
- Carglumic Acid remains on track to reach its goal of capturing 25-35% market share.
Challenges Ahead
- No specific negative forward-looking statements were found in the provided text.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...